Drug Profile
Research programme: multiple sclerosis therapeutics - Sanofi/Johns Hopkins University School of Medicine
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Johns Hopkins University School of Medicine
- Developer Johns Hopkins University School of Medicine; Sanofi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 16 May 2016 Early research in Multiple sclerosis in USA (unspecified route)